Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Vertex pays Alios $60M upfront with up to $715M in R&D milestones and $750M in sales milestones plus tiered royalties to access two nucleotide HCV polymerase…
Vertex entered an exclusive worldwide licensing accord with Alios BioPharma that added two distinct nucleotide analogues to Vertex's hepatitis C portfolio, at…
Incivek sales collapsed 96% YoY as Sovaldi displaced the protease class; Vertex announced it would exit hepatitis C R&D and out-license VX-135, ending the…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Vertex licensed two nucleotide analogues (ALS-2200/VX-135 and ALS-2158) from Alios for $60M upfront, up to $715M in R&D milestones, up to $750M in sales milestones, plus tiered royalties — total deal up to ~$1.5B. Strategic counter to Pharmasset HCV nucleotide platform.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / Alios BioPharma, Inc. (this deal) | 2011 | $1.5B | — |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. | 2026 | $10.0B | 68 |
← Browse all deals · How we score deals
More: 2011 deals · Vertex Pharmaceuticals Incorporated deals · Infectious Disease deals